Why Alterity Therapeutics, Flight Centre, NEXTDC, & Telix are surging higher

Flight Centre Travel Group Ltd (ASX:FLT) and NEXTDC Ltd (ASX:NXT) shares are two of four surging notably higher on Wednesday. Here's why…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The S&P/ASX 200 Index (ASX: XJO) is on course to start the new financial year with a solid gain. At the time of writing the benchmark index is up 0.65% to 5,936.2 points.

Four shares that have climbed more than most today are listed below. Here's why they are surging higher:

The Alterity Therapeutics Ltd (ASX: ATH) share price has rocketed an incredible 1,841% to 33 cents. Investors have been scrambling to buy the biotech company's shares after it revealed that its meeting with the U.S. FDA has provided it with a development pathway for its ATH434 candidate. ATH434 is the company's lead compound for the treatment of Multiple System Atrophy (MSA), a Parkinsonian disorder.

The Flight Centre Travel Group Ltd (ASX: FLT) share price has jumped 4.5% to $11.61. This morning the travel agent announced that it has secured access to a debt facility of up to 65 million pounds. These funds will be draw down if and when it is necessary to offset the coronavirus' impact on its United Kingdom-based operations. The funding has been made available to the company via the Bank of England's COVID Corporate Financing Facility.

The NEXTDC Ltd (ASX: NXT) share price has surged 6.5% higher to $10.53 after announcing major new contract wins in New South Wales. According to the release, the company's contracted commitments at its New South Wales data centre facilities have now increased by approximately 4MW, to more than 36MW. And including expansion options, its data centres in the state are now approaching a sizeable 60MW.

The Telix Pharmaceuticals Ltd (ASX: TLX) share price has jumped 16.5% to $1.49. The catalyst for this gain was an announcement which reveals that the U.S. FDA has granted Breakthrough Therapy designation for Telix's renal cancer imaging product TLX250-CDx. The FDA will work closely with Telix to provide guidance on the development of TLX250-CDx for the diagnosis of indeterminate renal masses that have been identified on CT or MRI imaging.

Motley Fool contributor James Mickleboro owns shares of NEXTDC Limited and TELIXPHARM DEF SET. The Motley Fool Australia has recommended Flight Centre Travel Group Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Share Gainers

3 ASX All Ords shares up 50%+ in March

These ASX shares have been on fire this month. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

Why Mesoblast, Patriot Battery Metals, Sigma, and Zip shares are pushing higher

These shares are having a good session on hump day. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Consumer Staples & Discretionary Shares

If you'd put $20,000 in this ASX retail stock at the start of 2023, you'd have $134,000 now

This online retailer has executed a remarkable turnaround for its investors.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was back to earth for ASX shares this Tuesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »